Merck expands PCR distribution agreement with Roche

Merck expands PCR distribution agreement with Roche

8:02 AM, 3rd December 2016
PCR and qPCR) enzyme products are of Kapa Biosystems
Polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products are of Kapa Biosystems.

DARMSTADT, GERMANY: Merck said that it has expanded its distribution cooperation with Roche Holding AG to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015.

The addition of the Kapa portfolio strengthens Merck’s existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR available in the industry today.

Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to present and distribute Kapa PCR and quantitative PCR reagents and kits. The distribution agreement includes all geographies except the US, Japan and Brazil.

Roche inked the global exclusive distribution agreement for its Biochemical Reagents portfolio with Sigma-Aldrich in July 2015. Following the acquisition of Sigma-Aldrich by Merck in the same year, this agreement became an important part of Merck, driving growth in its life science business and offering premier brand tools for genomics, proteomics and cell analysis.

The novel PCR enzymes offered under the expanded distribution agreement have improved tolerance to common PCR inhibitors, increased speed and specific activity, and higher fidelity. These characteristics enable higher quality results and improved workflows.

The transition of Kapa’s PCR and qPCR portfolios to Merck is expected to be completed by 1 January 2017.

“The alliance extension with Roche will offer our customers greater access to novel products via our world-class distribution channel. These enzymes represent a significant advantage over commercially available DNA polymerases and thus offer the potential for entirely new PCR applications,” said Udit Batra, member of the Merck executive board and CEO, Life Science.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


BASF bags the German Federal Ecodesign Award for ‘cool coatings’

LUDWIGSHAFEN, GERMANY: BASF's coatings division has won the German Federal Ecodesign Award. The board was convinced by the "cool coatings" automotive ...

Read more
Yoga practise help transform your genetics: study

OSLO, NORWAY: A recent study by researchers from the University of Oslo, Norway found that Yoga and Sudarshan Kriya can substantially change the genes ...

Read more
Digital era dominates the chemical industry

Editorial of Chemical Today magazine. A few years ago, one common early morning scene in all houses would be – the delivery of the newspaper. ...

Read more
Calumet completes expansion of its blending facility in US

INDIANAPOLIS, US: Calumet Specialty Products Partners LP (CLMT) said that it has partnered with BP Lubricants USA to begin blending Castrol Motor Oil ...

Read more
Chevron names new president for Africa, Latin America E&P unit

SAN RAMON, US: Chevron Corporation (CVX) has appointed Clay Neff (54) as the president of Chevron Africa and Latin America Exploration and Production ...

Read more
The good ol days!

Editorial of Chemical Today magazine. Remember the good ol days! - When soap was just a red colour bar and a detergent was the rough, solid, white ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X